PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 153 filers reported holding PROTAGONIST THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.62 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,185 | -39.6% | 131 | 0.0% | 0.00% | -50.0% |
| Q2 2023 | $3,618 | +20.1% | 131 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $3,013 | -20.0% | 131 | -62.0% | 0.00% | 0.0% |
| Q4 2022 | $3,764 | +25.5% | 345 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $3,000 | 0.0% | 345 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $3,000 | -66.7% | 345 | +38.0% | 0.00% | -60.0% |
| Q4 2021 | $9,000 | +125.0% | 250 | 0.0% | 0.01% | +150.0% |
| Q3 2021 | $4,000 | -63.6% | 250 | 0.0% | 0.00% | -66.7% |
| Q2 2021 | $11,000 | +83.3% | 250 | 0.0% | 0.01% | +100.0% |
| Q1 2021 | $6,000 | +200.0% | 250 | +110.1% | 0.00% | +200.0% |
| Q4 2020 | $2,000 | 0.0% | 119 | 0.0% | 0.00% | -50.0% |
| Q2 2020 | $2,000 | +100.0% | 119 | 0.0% | 0.00% | +100.0% |
| Q3 2019 | $1,000 | 0.0% | 119 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $1,000 | 0.0% | 119 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $1,000 | -66.7% | 119 | -52.8% | 0.00% | 0.0% |
| Q3 2018 | $3,000 | – | 252 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $67,646,434 | 21.00% |
| COWEN AND COMPANY, LLC | 1,657,551 | $45,781,558 | 3.80% |
| Kynam Capital Management, LP | 975,298 | $26,937,731 | 3.70% |
| BVF INC/IL | 3,775,900 | $104,290,358 | 2.91% |
| RTW INVESTMENTS, LP | 5,415,514 | $149,576,497 | 2.85% |
| Cormorant Asset Management, LP | 1,500,000 | $41,430,000 | 2.32% |
| Ghost Tree Capital, LLC | 225,000 | $6,214,500 | 2.05% |
| 683 Capital Management, LLC | 814,000 | $22,482,680 | 1.62% |
| Perceptive Advisors | 1,469,761 | $40,594,799 | 1.18% |
| Artia Global Partners LP | 112,340 | $3,102,831 | 1.07% |